Brazilian Cardio-oncology Guideline - 2020.
Ontology highlight
ABSTRACT:
SUBMITTER: Hajjar LA
PROVIDER: S-EPMC8452206 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Publications
Brazilian Cardio-oncology Guideline - 2020.
Hajjar Ludhmila Abrahão LA Costa Isabela Bispo Santos da Silva da IBSDSD Lopes Marcelo Antônio Cartaxo Queiroga MACQ Hoff Paulo Marcelo Gehm PMG Diz Maria Del Pilar Estevez MDPE Fonseca Silvia Moulin Ribeiro SMR Bittar Cristina Salvadori CS Rehder Marília Harumi Higuchi Dos Santos MHHDS Rizk Stephanie Itala SI Almeida Dirceu Rodrigues DR Fernandes Gustavo Dos Santos GDS Beck-da-Silva Luís L Campos Carlos Augusto Homem de Magalhães CAHM Montera Marcelo Westerlund MW Alves Sílvia Marinho Martins SMM Fukushima Júlia Tizue JT Santos Maria Verônica Câmara Dos MVCD Negrão Carlos Eduardo CE Silva Thiago Liguori Feliciano da TLFD Ferreira Silvia Moreira Ayub SMA Malachias Marcus Vinicius Bolivar MVB Moreira Maria da Consolação Vieira MDCV Valente Neto Manuel Maria Ramos MMR Fonseca Veronica Cristina Quiroga VCQ Soeiro Maria Carolina Feres de Almeida MCFA Alves Juliana Barbosa Sobral JBS Silva Carolina Maria Pinto Domingues Carvalho CMPDC Sbano João J Pavanello Ricardo R Pinto Ibraim Masciarelli F IMF Simão Antônio Felipe AF Dracoulakis Marianna Deway Andrade MDA Hoff Ana Oliveira AO Assunção Bruna Morhy Borges Leal BMBL Novis Yana Y Testa Laura L Alencar Filho Aristóteles Comte de AC Cruz Cecília Beatriz Bittencourt Viana CBBV Pereira Juliana J Garcia Diego Ribeiro DR Nomura Cesar Higa CH Rochitte Carlos Eduardo CE Macedo Ariane Vieira Scarlatelli AVS Marcatti Patricia Tavares Felipe PTF Mathias Junior Wilson W Wiermann Evanius Garcia EG Val Renata do RD Freitas Helano H Coutinho Anelisa A Mathias Clarissa Maria de Cerqueira CMC Vieira Fernando Meton de Alencar Camara FMAC Sasse André Deeke AD Rocha Vanderson V Ramires José Antônio Franchini JAF Kalil Filho Roberto R
Arquivos brasileiros de cardiologia 20201101 5
Similar Datasets
Project description:Echocardiographic imaging is crucial for patient management during cardiotoxic cancer therapy. Left ventricular ejection fraction is the most commonly used parameter for identifying left ventricular dysfunction. However, it lacks sensitivity to detect subclinical changes in cardiac function due to cardiotoxic treatment. Global longitudinal strain (GLS) is the best studied strain parameter with established diagnostic and prognostic value. Multiple studies have demonstrated changes in GLS as an early marker of cardiotoxicity. This document serves as a primer to help clinicians in the acquisition and interpretation of strain in cardio-oncology. Cases with embedded videos illustrate a step-by-step approach to obtaining GLS measurements and common pitfalls to avoid. The document includes a concise summary of the indications of GLS in cardio-oncology and its role in guiding oncological therapy. Practical approaches on how to implement strain in the echo laboratory with guidance on training and quality assurance are also discussed.
| S-EPMC8352045 | biostudies-literature
Project description: Not available
| S-EPMC6402516 | biostudies-literature
Project description:BackgroundChemotherapy induced cardio-toxicity has been recognized as a serious side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity among patients with breast cancer is well studied but the impact on patients with sarcoma is limited, even though they are exposed to higher ANT doses. The commonly used term for cardio-toxicity is cancer therapeutics related cardiac dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF) reduction of > 10%, to a value below 53%. The aim of our study was to estimate the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the baseline risk factors and echocardiography parameters among that population.MethodsData were collected as part of the Israel Cardio-Oncology Registry (ICOR), enrolling all patients evaluated in the cardio-oncology clinic at our institution. The registry was approved by the local ethics committee and is registered in clinicaltrials.gov (Identifier: NCT02818517). All sarcoma patients were enrolled and divided into two groups - CTRCD group vs. non-CTRCD group.ResultsAmong 43 consecutive patients, 6 (14%) developed CTRCD. Baseline cardiac risk factors were more frequent among the non-CTRCD group. Elevated left ventricular end systolic diameter and reduced Global Longitudinal Strain were observed among the CTRCD group. During follow-up, 2 (33%) patients died in the CTRCD group vs. 3 (8.1%) patients in the non-CTRCD group.ConclusionsCTRCD is an important concern among patients with sarcoma, regardless of baseline risk factors. Echocardiography parameters may provide an early diagnosis of cardio-toxicity.
| S-EPMC7325299 | biostudies-literature
Project description:Heart disease and cancer are the leading causes of death in older adults. Many first-line cancer treatments have the potential for cardiotoxicity. Age-related risk factors, pre-existing cardiac disease, and a high prevalence of comorbidities are reasons for increased cardiotoxicity in older adults. Concerns regarding cardiotoxicity may lead to frailty bias and undertreatment, resulting in suboptimal outcomes. There is an urgent need for geriatric-specific evidence and guidelines to help tailor care for this vulnerable group. A multi-disciplinary approach based on close collaboration between oncologists, cardiologists, and geriatricians, among other specialist clinicians is essential.
| S-EPMC5776715 | biostudies-other
Project description:Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.
| S-EPMC8984624 | biostudies-literature
Project description:The genomic predisposition to oncology-drug-induced cardiovascular toxicity has been postulated for many decades. Only recently has it become possible to experimentally validate this hypothesis via the use of patient-specific human-induced pluripotent stem cells (hiPSCs) and suitably powered genome-wide association studies (GWAS). Identifying the individual single nucleotide polymorphisms (SNPs) responsible for the susceptibility to toxicity from a specific drug is a daunting task as this precludes the use of one of the most powerful tools in genomics: comparing phenotypes to close relatives, as these are highly unlikely to have been treated with the same drug. Great strides have been made through the use of candidate gene association studies (CGAS) and increasingly large GWAS studies, as well as in vivo whole-organism studies to further our mechanistic understanding of this toxicity. The hiPSC model is a powerful technology to build on this work and identify and validate causal variants in mechanistic pathways through directed genomic editing such as CRISPR. The causative variants identified through these studies can then be implemented clinically to identify those likely to experience cardiovascular toxicity and guide treatment options. Additionally, targets identified through hiPSC studies can inform future drug development. Through careful phenotypic characterization, identification of genomic variants that contribute to gene function and expression, and genomic editing to verify mechanistic pathways, hiPSC technology is a critical tool for drug discovery and the realization of precision medicine in cardio-oncology.
| S-EPMC6452310 | biostudies-literature
Project description: Not available
| S-EPMC6965025 | biostudies-literature
Project description:IntroductionNational data on chronic dialysis treatment are essential to support the development of health policies aimed at improving the treatment for thousands of people.ObjectiveTo report epidemiological data from the 2020 Brazilian Dialysis Survey, sponsored by the Brazilian Society of Nephrology.MethodsA survey was carried out in Brazilian chronic dialysis centers using an online questionnaire for the year, covering clinical and epidemiological aspects of patients in a chronic dialysis program, data on dialysis therapy, characteristics of dialysis units and the impact of the COVID-19 pandemic.Results235 (28%) of the centers responded to the questionnaire. In July 2020, the estimated total number of patients on dialysis was 144,779. The estimated prevalence and incidence rates of patients per million population (pmp) were 684 and 209, respectively. Of the prevalent patients, 92.6% were on hemodialysis (HD) and 7.4% were on peritoneal dialysis (PD); 23% were on the transplant waiting list. A central venous catheter was used by a quarter of patients on HD. The incidence rate of confirmed COVID-19 between February and July 2020 was 684/10,000 dialysis patients, and the lethality rate was 25.7%. The estimated overall mortality and COVID-19 crude annual mortality rates were 24.5 and 4.2%, respectively.ConclusionThe absolute number of patients on chronic dialysis and prevalence rate continued to increase. The low use of PD as dialysis therapy was maintained and the use of long-term catheters for HD increased. The COVID-19 pandemic contributed to the increase in the overall mortality rate.
| S-EPMC9518621 | biostudies-literature
Project description:With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.
| S-EPMC6452306 | biostudies-literature
Project description:BackgroundThe relative new subspecialty 'cardio-oncology' was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy-related cardiovascular adverse events. In recent years, specialised cardio-oncology services have been implemented worldwide, which all strive to improve the cardiovascular health of cancer patients. However, limited data are currently available on the outcomes and experiences of these specialised services, and optimal strategies for cardio-oncological care have not been established.AimThe ONCOR registry has been created for prospective data collection and evaluation of cardio-oncological care in daily practice.MethodsDutch hospitals using a standardised cardio-oncology care pathway are included in this national, multicentre, observational cohort study. All patients visiting these cardio-oncology services are eligible for study inclusion. Data collection at baseline consists of the (planned) cancer treatment and the cardiovascular risk profile, which are used to estimate the cardiotoxic risk. Information regarding invasive and noninvasive tests is collected during the time patients receive cardio-oncological care. Outcome data consist of the incidence of cardiovascular complications and major adverse cardiac events, and the impact of these events on the oncological treatment.DiscussionOutcomes of the ONCOR registry may aid in gaining more insight into the incidence of cancer therapy-related cardiovascular complications. The registry facilitates research on mechanisms of cardiovascular complications and on diagnostic, prognostic and therapeutic strategies. In addition, it provides a platform for future (interventional) studies. Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate.
| S-EPMC8062648 | biostudies-literature